STAT1 and neoplasm: Existing studies have confirmed that the STAT3-mediated inhibitory tumor immune response pathway has an antagonistic effect on the STAT1-driven antitumor immune response, which may lead to the loss of IFNγ/JAK/STAT1 pathway function (Figure 7).